Featured Research

from universities, journals, and other organizations

How our liver kills 'killer cells'

Date:
September 22, 2011
Source:
Centenary Institute
Summary:
Our livers can fight back against the immune system -- reducing organ rejection but also making us more susceptible to liver disease. Scientists have seen for the first time (in mice) how the liver goes independent, engulfing and destroying the body's defense troops -- T-cells. Their discovery opens the way to both new approaches to transplant rejection, and to the fight against hepatitis and other chronic liver diseases.

A T-cell (blue/green) is fully engulfed by a mouse liver cell (red). The two blue circles are the cell nuclei of the liver cell.
Credit: Patrick Bertolino/Centenary Institute

Our livers can fight back against the immune system -- reducing organ rejection but also making us more susceptible to liver disease. Scientists at the Centenary Institute in Sydney have seen for the first time (in mice) how the liver goes independent, engulfing and destroying the body's defence troops -- T-cells.

Their discovery, published overnight in PNAS (Proceedings of the National Academy of Sciences), opens the way to both new approaches to transplant rejection, and to the fight against hepatitis and other chronic liver diseases which affect over 200,000 Australians and hundreds of millions of people worldwide.

"In 2004, we discovered that healthy liver cells can engulf active immune cells, known as T-cells -- and now we've seen that those T-cells are actually destroyed," says Dr Patrick Bertolino, the leader of the research team at the Centenary Institute.

"The liver is an amazing organ," Dr Bertolino says. "Most people think it just breaks down alcohol, but it's the factory of the body -- breaking down substances we don't want and making the ones that we do.

"We now know liver cells also have the ability to subvert the orders of the immune system," he says, "Our discovery might explain why liver transplants have lower rejection rates than other organ transplants."

"When Patrick first told me he had evidence T-cells might be eaten by liver cells, showing a possible link to the liver's ability to dial down the immune response, I thought the idea was crazy," says lead author Volker Benseler. But Volker accepted Patrick's challenge to prove it and went on to find healthy mouse liver cells eating T-cells, which was unexpected as this 'cell cannibalism' had only previously been seen in tumour cells.

One potential benefit of the research is reducing rejection in organ transplants. About 200 liver transplants are performed in Australia each year and up to 25 per cent of cases end in rejection.

In transplantation, the new organ is seen by the body as a foreign object: the spleen or lymph nodes tell naοve T-cells to replicate and turn into killer T-cells, which are sent off to invade and kill the 'foreign' cells.

What the researchers have discovered is the liver goes around this process: liver cells signal to naοve T-cells and digest them before they have a chance to become killer T-cells.

Centenary Institute's Liver Unit leader, Professor Geoff McCaughan, says the cocktail of immunosuppressive drugs that organ transplant patients receive reduce the odds of organ rejection but makes patients' immune systems weak, leaving them open to serious infection from otherwise minor illnesses like cold or flu. These drugs also predispose the patient to long-term heart disease and cancer. "If we can harness the way the liver controls T-cells, then long-term there is a chance that transplant patients won't need these drugs," he says.

Another spin-off of this latest work could be to find a way to dial down the liver's destruction of T-cells, increasing the liver's defence against infections like hepatitis.

In Australia, 217,000 people are living with chronic hepatitis C and it is estimated that 170 million people worldwide are infected with hepatitis C, for which there is no vaccine.

Exploiting signalling pathways between the liver and the T-cells is one possible outcome of this discovery, but first the molecular biology that underpins those pathways will need to be worked out.

"It could be another ten years plus before we see drugs derived from this work enter clinical trials," Dr Bertolino says.

However, the research opens up a new question -- why? "We don't yet know why the liver has developed this ability," says Dr Bertolino. "The discovery reminds us that we still have a lot to learn about the liver."

The work was conducted at the Centenary Institute and at Sydney's Concord RG Hospital, at the ANZAC Research Institute and CERA. Dr Benseler is now completing surgical training in Germany.


Story Source:

The above story is based on materials provided by Centenary Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Volker Benseler, Alessandra Warren, Michelle Vo, Lauren E. Holz, Szun S. Tay, David G. Le Couteur, Eamon Breen, Anthony C. Allison, Nico Van Rooijen, Claire Mcguffog, Hans J. Schlitt, David G. Bowen, Geoffrey W. Mccaughan, Patrick Bertolino. Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proceedings of the National Academy of Sciences, 2011; DOI: 10.1073/pnas.1112251108

Cite This Page:

Centenary Institute. "How our liver kills 'killer cells'." ScienceDaily. ScienceDaily, 22 September 2011. <www.sciencedaily.com/releases/2011/09/110919151324.htm>.
Centenary Institute. (2011, September 22). How our liver kills 'killer cells'. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/09/110919151324.htm
Centenary Institute. "How our liver kills 'killer cells'." ScienceDaily. www.sciencedaily.com/releases/2011/09/110919151324.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins